PubRank

Robert W Brueggemeier

Author PubWeight™ 37.47‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab 2005 1.56
2 Reconsidering the length of program accreditation. Am J Pharm Educ 2011 1.44
3 Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem 2006 1.19
4 Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis 2003 1.16
5 Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther 2008 1.15
6 Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol Pharmacol 2005 1.13
7 Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes. J Clin Endocrinol Metab 2003 1.12
8 Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 2006 1.12
9 The final catalytic step of cytochrome p450 aromatase: a density functional theory study. J Am Chem Soc 2005 1.08
10 Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells. J Steroid Biochem Mol Biol 2002 1.05
11 Are we producing innovators and leaders or change resisters and followers? Am J Pharm Educ 2012 1.00
12 Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008 0.99
13 Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem 2006 0.99
14 Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int J Pharm 2010 0.97
15 Synthesis and biological evaluation of novel sulfonanilide compounds as antiproliferative agents for breast cancer. J Comb Chem 2008 0.93
16 Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer. Cancer Res 2011 0.92
17 Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem 2007 0.90
18 Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem 2003 0.88
19 Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay. J Nat Prod 2006 0.88
20 SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm 2011 0.88
21 Xanthones from the botanical dietary supplement mangosteen (Garcinia mangostana) with aromatase inhibitory activity. J Nat Prod 2008 0.87
22 Suppression of aromatase in human breast cells by a cyclooxygenase-2 inhibitor and its analog involves multiple mechanisms independent of cyclooxygenase-2 inhibition. Steroids 2007 0.85
23 Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification. J Med Chem 2008 0.84
24 Increasing the DNA damage threshold in breast cancer cells. Toxicol Appl Pharmacol 2002 0.84
25 Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer. Nanomedicine 2012 0.83
26 Synthesis and estrogen receptor binding affinities of 7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-ones containing a basic side chain. Bioorg Med Chem Lett 2003 0.83
27 Synthesis and characterization of azole isoflavone inhibitors of aromatase. Bioorg Med Chem 2005 0.82
28 Natural products as aromatase inhibitors. Anticancer Agents Med Chem 2008 0.82
29 Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer. Clin Breast Cancer 2011 0.82
30 Influence of novel KGFR tyrosine kinase inhibitors on KGF-mediated proliferation of breast cancer. Anticancer Res 2010 0.81
31 Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors. Bioorg Med Chem 2005 0.81
32 Differential efficacy of DOTAP enantiomers for siRNA delivery in vitro. Int J Pharm 2012 0.81
33 Role of the azinomycin naphthoate and central amide in sequence-dependent DNA alkylation and cytotoxicity of epoxide-bearing substructures. Org Lett 2002 0.80
34 Synthesis and aromatase inhibitory activity of novel pyridine-containing isoflavones. J Med Chem 2004 0.80
35 Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells. J Steroid Biochem Mol Biol 2007 0.79
36 Maintaining pharmacy education's research focus as the academy expands. Am J Pharm Educ 2012 0.78
37 Isolation and Characterization of Aromatase Inhibitors from Brassaiopsis glomerulata (Araliaceae). Phytochem Lett 2009 0.77
38 Development of keratinocyte growth factor receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Res 2008 0.76
39 Highly efficient cationic ethylphosphatidylcholine siRNA carrier for GFP suppression in modified breast cancer cells. Anticancer Res 2012 0.75
40 Rapamycin-loaded immunoliposomes functionalized with trastuzumab: a strategy to enhance cytotoxicity to HER2-positive breast cancer cells. Anticancer Agents Med Chem 2016 0.75
41 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. J Steroid Biochem Mol Biol 2007 0.75